Inovio Pharmaceuticals, Inc.
INO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $1 | $10 | $2 |
| % Growth | -73.8% | -91.9% | 478.2% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $1 | $10 | $2 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $76 | $87 | $188 | $249 |
| G&A Expenses | $37 | $48 | $90 | $54 |
| SG&A Expenses | $37 | $48 | $90 | $54 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $11 | $0 | $0 |
| Operating Expenses | $113 | $145 | $278 | $303 |
| Operating Income | -$112 | -$144 | -$268 | -$301 |
| % Margin | -51,616.9% | -17,300.3% | -2,607.4% | -16,972.3% |
| Other Income/Exp. Net | $5 | $9 | -$12 | -$2 |
| Pre-Tax Income | -$107 | -$135 | -$280 | -$304 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$107 | -$135 | -$280 | -$304 |
| % Margin | -49,254.3% | -16,239.9% | -2,726.7% | -17,109.9% |
| EPS | -3.95 | -6.09 | -14.07 | -1.42 |
| % Growth | 35.1% | 56.7% | -890.8% | – |
| EPS Diluted | -3.95 | -6.09 | -14.07 | -1.42 |
| Weighted Avg Shares Out | 27 | 22 | 20 | 215 |
| Weighted Avg Shares Out Dil | 27 | 22 | 20 | 215 |
| Supplemental Information | – | – | – | – |
| Interest Income | $5 | $8 | $5 | $3 |
| Interest Expense | $0 | $1 | $1 | $2 |
| Depreciation & Amortization | $3 | $4 | $5 | $5 |
| EBITDA | -$104 | -$130 | -$271 | -$297 |
| % Margin | -47,735.2% | -15,671.8% | -2,639.8% | -16,709.7% |